Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and ...

Early prophylaxis reduces bone loss in haemophilia, while delayed or absent treatment increases osteoporosis risk.

Dr. Nigel Key and Dr. Anna Falanga join us for a conversation on the updated ASCO VTE prophylaxis and treatment in patients with cancer guideline. They discuss recent evidence assessing apixaban for ...

Methods We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses ...

Please provide your email address to receive an email when new articles are posted on . The monoclonal antibody significantly reduced both treated spontaneous and traumatic bleeds among individuals ...

Please provide your email address to receive an email when new articles are posted on . Patients who received prophylactic concizumab had a mean overall annualized bleeding rate of zero compared with ...

If approved, marstacimab would be the first non-factor prophylactic treatment indicated for pediatric patients aged 6 to 11 years with hemophilia B.

Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...